AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7849442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 3059450 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (3 g)
Number of subjects: 29
Study 3059450 — intervention group
Group type: COMPARATOR
Intervention: prednisolone phosphate sodium (30 mg)
Number of subjects: 29
Study 30726338 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching program for hospital discharge (oral guidance, written instruction, telephone follow-up)
Number of subjects: 68
Study 30726338 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching program for hospital discharge
Number of subjects: 68
Study 30726338 — intervention group
Group type: COMPARATOR
Intervention: Routine guidance from the service
Number of subjects: 68
Study 28806992 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month clustered campaign program (12 group-based visits delivered in three, 4-week clusters)
Number of subjects: 108
Study 28806992 — intervention group
Group type: COMPARATOR
Intervention: Self-directed program (provision of printed intervention materials but no additional treatment visits)
Number of subjects: 108
Study 25415805 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer (4.2 g or 8.4 g twice a day for 4 weeks)
Number of subjects: 237
Study 25415805 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 237
Study 25415805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 22433185 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg L-759274
Number of subjects: 213
Study 22433185 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-6 mg lorazepam
Number of subjects: 213
Study 22433185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 22035427 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led care (MLU)
Number of subjects: 1653
Study 18327829 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and neurological testimony (presence of MRI indicating a brain lesion and testimony about brain injury)
Number of subjects: 396
Study 18327829 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and neurological testimony (influence on decision-making)
Number of subjects: 396
Study 16882822 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychosocial support from a member of the primary care team, with or without medication
Number of subjects: 37
Study 16882822 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-delivered psychosocial interventions
Number of subjects: 37
Study 16882822 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect psychosocial/behavioral interventions (e.g., anticipatory guidance, treatment adherence)
Number of subjects: 37
Study 16882822 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider training to enhance psychosocial skills
Number of subjects: 37
Study 12821755 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment (anticholesterol drugs)
Number of subjects: 37
Study 10849926 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution in Myvacet 9-08
Number of subjects: 7
Study 10849926 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspension of phenobarbital
Number of subjects: 7
Study 10849926 — intervention group
Group type: COMPARATOR
Intervention: Tablet of phenobarbital
Number of subjects: 7
Study 8992495 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (NE) administration
Number of subjects: 8
Study 8992495 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin pretreatment with NE
Number of subjects: 8
Study 8992495 — intervention group
Group type: COMPARATOR
Intervention: Dextrose 5%
Number of subjects: 8
Study 1379106 — intervention group
Group type: EXPERIMENTAL
Intervention: alfuzosin 1.25 mg
Number of subjects: 93
Study 1379106 — intervention group
Group type: EXPERIMENTAL
Intervention: alfuzosin 2.5 mg
Number of subjects: 93
Study 1379106 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 93
Study 6707391 — intervention group
Group type: EXPERIMENTAL
Intervention: PRW therapy (4 injections)
Number of subjects: 63
Study 6707391 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (4 injections)
Number of subjects: 63
Study 6707391 — intervention group
Group type: COMPARATOR
Intervention: No injections (control group)
Number of subjects: 63
Study 29477903 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention for alcohol risk reduction
Number of subjects: 264
Study 29477903 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention for sexual assault risk reduction
Number of subjects: 264
Study 29477903 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback intervention for combined alcohol and sexual assault risk reduction
Number of subjects: 264
Study 29477903 — intervention group
Group type: COMPARATOR
Intervention: Control condition (full or minimal assessment)
Number of subjects: 264
Study 26729211 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 40
Study 26729211 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (L)
Number of subjects: 40
Study 26729211 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium dose (M)
Number of subjects: 40
Study 26729211 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (H)
Number of subjects: 40
Study 25908774 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote rhythm monitoring with anticoagulation based on AT detection
Number of subjects: 2718
Study 25908774 — intervention group
Group type: COMPARATOR
Intervention: Usual office-based follow-up with anticoagulation determined by standard clinical criteria
Number of subjects: 2718
Study 23616630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol ablation (EA)
Number of subjects: 50
Study 23616630 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 50
Study 23616630 — intervention group
Group type: COMPARATOR
Intervention: Ethanol ablation (EA) and Radiofrequency ablation (RF)
Number of subjects: 50
Study 20674390 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive exercise program with weekly supervision
Number of subjects: 100
Study 20674390 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (control)
Number of subjects: 100
Study 18426821 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1 g twice daily)
Number of subjects: 96
Study 18426821 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide (2 mg thrice daily)
Number of subjects: 96
Study 16635750 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (0.5, 2.5, or 5mg FTY/day)
Number of subjects: 14
Study 16635750 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 (0.25mg FTY/day)
Number of subjects: 14
Study 16635750 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 14
Study 14668594 — intervention group
Group type: EXPERIMENTAL
Intervention: Parks retractor
Number of subjects: 30
Study 14668594 — intervention group
Group type: COMPARATOR
Intervention: Scott retractor
Number of subjects: 30
Study 10616075 — intervention group
Group type: EXPERIMENTAL
Intervention: N-methyl-D-aspartate antagonist Selfotel
Number of subjects: 427
Study 10616075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial hypertension (ICP > or = 20 mm Hg)
Number of subjects: 427
Study 10616075 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure (CPP > 60 mm Hg)
Number of subjects: 427
Study 9169302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol 12 g daily for 4 weeks
Number of subjects: 28
Study 9169302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol 18 g for 6 weeks
Number of subjects: 28
Study 9169302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol 12 g daily for 1 month
Number of subjects: 28
Study 9169302 — intervention group
Group type: COMPARATOR
Intervention: Inositol 6 g daily for 1 month
Number of subjects: 28
Study 9169302 — intervention group
Group type: COMPARATOR
Intervention: Inositol 200 mg/kg body weight for 8 weeks
Number of subjects: 28
Study 9169302 — intervention group
Group type: COMPARATOR
Intervention: Inositol 200 mg/kg daily for a crossover trial
Number of subjects: 28
Study 9169302 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol 6 g daily for 5 days before ECT
Number of subjects: 28
Study 8289407 — intervention group
Group type: EXPERIMENTAL
Intervention: GLN-containing total parenteral nutrition (TPN) (40 g of glutamine total)
Number of subjects: 23
Study 8289407 — intervention group
Group type: COMPARATOR
Intervention: Standard total parenteral nutrition (TPN) (control)
Number of subjects: 23
Study 3026015 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulbactam (50 mg/kg per day) and ampicillin (400 mg/kg per day)
Number of subjects: 81
Study 3026015 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol and ampicillin
Number of subjects: 81
Study 30275753 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial shockwave therapy (0.17mJ/mm2, 100 impulses/cm2, 5 Hz)
Number of subjects: 0
Study 30275753 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused shockwave therapy (0.173mJ/mm2, 100 impulses/cm2, 5 Hz)
Number of subjects: 0
Study 30275753 — intervention group
Group type: COMPARATOR
Intervention: Standard wound care (SWC)
Number of subjects: 0
Study 26908801 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV-HD (High-Dose Inactivated Influenza Vaccine)
Number of subjects: 7643
Study 26908801 — intervention group
Group type: COMPARATOR
Intervention: IIV-SD (Standard-Dose Inactivated Influenza Vaccine)
Number of subjects: 7643
Study 24881861 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 1612
Study 24881861 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 1612
Study 24131759 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide (single injection)
Number of subjects: 60
Study 24131759 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide (repeat injection at 21-day interval)
Number of subjects: 60
Study 24131759 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroid injection)
Number of subjects: 60
Study 21927044 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic adjustment of spinal cord stimulation amplitude
Number of subjects: 20
Study 21927044 — intervention group
Group type: COMPARATOR
Intervention: Manual adjustment of spinal cord stimulation amplitude
Number of subjects: 20
Study 18185520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotransplantation of mesenchymal stem cells (MSCs), median number infused: 3.4 x 10(5) kg(‐1) (range, 0.3‐15.3 x 10(5) kg(‐1))
Number of subjects: 25
Study 18185520 — intervention group
Group type: COMPARATOR
Intervention: HLA‐identical sibling‐matched hematopoietic stem cells (HSC) without MSCs (non-MSCs group)
Number of subjects: 25
Study 16343417 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastic chewing gum
Number of subjects: 25
Study 16343417 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 25
Study 14607583 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete hatching using the Zona Infrared Laser Optical System (ZILOS)
Number of subjects: 114
Study 14607583 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial hatching using the Zona Infrared Laser Optical System (ZILOS)
Number of subjects: 114
Study 14607583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser treatment)
Number of subjects: 114
Study 10974832 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation radiotherapy (7 fx a week)
Number of subjects: 0
Study 10974832 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (5 fx a week)
Number of subjects: 0
Study 10974832 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment (total laryngectomy + postoperative RT)
Number of subjects: 0
Study 8816612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg/wk)
Number of subjects: 29
Study 8816612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1579279 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (E) - parents brought only their sick child into the examining room
Number of subjects: 49
Study 1579279 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - parents brought their well children along with their sick child into the examining room
Number of subjects: 49
Study 3915460 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 20 mg + Piretanide 3 mg
Number of subjects: 108
Study 3915460 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg + Piretanide 6 mg
Number of subjects: 108
Study 3915460 — intervention group
Group type: COMPARATOR
Intervention: Penbutolol 20 mg
Number of subjects: 108
Study 29797226 — intervention group
Group type: EXPERIMENTAL
Intervention: Contra-lesional cerebellar tDCS
Number of subjects: 15
Study 29797226 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 15
Study 29797226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsi-lesional cerebellar tDCS
Number of subjects: 15
Study 29797226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsi-lateral cerebellar stimulation in healthy controls
Number of subjects: 15
Study 27442637 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat transforaminal epidural steroid injection (TFESI) at 2 to 3 weeks after the first injection
Number of subjects: 184
Study 27442637 — intervention group
Group type: COMPARATOR
Intervention: Intermittent transforaminal epidural steroid injection (TFESI) only for pain aggravation
Number of subjects: 184
Study 24670570 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 167
Study 24670570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 23141790 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild shock or surprise stimuli exposure for one twin during a 12-minute period; physiological responses recorded in the second twin.
Number of subjects: 8
Study 21029903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical microkeratome (Carriazo‐Barraquer)
Number of subjects: 50
Study 21029903 — intervention group
Group type: COMPARATOR
Intervention: Femtosecond laser (IntraLase)
Number of subjects: 50
Study 21029903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Mechanical microkeratome and Femtosecond laser)
Number of subjects: 50
Study 18545825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - Lateral decubitus position facing away from the ventilator (Pcuff A1)
Number of subjects: 70
Study 18545825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - Return to initial position (Pcuff A2)
Number of subjects: 70
Study 18545825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - Lateral decubitus position facing the ventilator (Pcuff A3)
Number of subjects: 70
Study 18545825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - Return to initial position (Pcuff A4)
Number of subjects: 70
Study 18545825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - Lateral decubitus position facing the ventilator (Pcuff B1)
Number of subjects: 70
Study 18545825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - Return to initial position (Pcuff B2)
Number of subjects: 70
Study 18545825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - Lateral decubitus position facing away from the ventilator (Pcuff B3)
Number of subjects: 70
Study 18545825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B - Return to initial position (Pcuff B4)
Number of subjects: 70
Study 18545825 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall measurements
Number of subjects: 70
Study 19855315 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (100 mg three times daily for 7 days)
Number of subjects: 12
Study 15066920 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-group risk communication intervention varying information on CRC risk factors and tailored feedback.
Number of subjects: 860
Study 15066920 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-group risk communication intervention
Number of subjects: 860
Study 11570312 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly injectable combination hormone contraceptive
Number of subjects: 0
Study 11570312 — intervention group
Group type: COMPARATOR
Intervention: Oral contraceptive
Number of subjects: 0
Study 9720517 — intervention group
Group type: EXPERIMENTAL
Intervention: UroPhos-K (4 tablets twice daily)
Number of subjects: 31
Study 9720517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8147942 — intervention group
Group type: EXPERIMENTAL
Intervention: Promazine (100 mg orally)
Number of subjects: 12
Study 8147942 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (150 mg orally)
Number of subjects: 12
Study 8147942 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (75 mg orally)
Number of subjects: 12
Study 8147942 — intervention group
Group type: EXPERIMENTAL
Intervention: Promazine (20 mg intravenously)
Number of subjects: 12
Study 8147942 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg intravenously)
Number of subjects: 12
Study 8147942 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine (50 mg intravenously)
Number of subjects: 12
Study 2849461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin (70 mg/m2) and etoposide (100 mg/m2), given every third week for a maximum of 4 cycles
Number of subjects: 0
Study 2849461 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (42 Gy)
Number of subjects: 0
Study 2849461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with cisplatin and etoposide
Number of subjects: 0
Study 31121903 — intervention group
Group type: EXPERIMENTAL
Intervention: Smog warning system
Number of subjects: 1328
Study 31121903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smog warning)
Number of subjects: 1328
Study 29474863 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise training for 24 weeks
Number of subjects: 61
Study 26455512 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Folic Acid (10 mg enalapril and 0.8 mg folic acid)
Number of subjects: 20702
Study 26455512 — intervention group
Group type: COMPARATOR
Intervention: Enalapril alone (10 mg enalapril)
Number of subjects: 20702
Study 26455512 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril + Folic Acid
Number of subjects: 20702
Study 23846159 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) 70 mL
Number of subjects: 9
Study 23846159 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (PLA)
Number of subjects: 9
Study 22127418 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring follow-up (active group)
Number of subjects: 538
Study 22127418 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 538
Study 19715804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal analgesic (levobupivacaine 0.5%)
Number of subjects: 71
Study 19715804 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% NaCl)
Number of subjects: 71
Study 17344574 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic gallbladder drainage (PTGD)
Number of subjects: 101
Study 17344574 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography (ERCP)
Number of subjects: 101
Study 17344574 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 101
Study 17344574 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 101
Study 15613148 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 0
Study 15613148 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0
Study 12189242 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic parenteral nutrition (IDPN)
Number of subjects: 7
Study 11021270 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and insulin-like growth factor-I (IGF-I) treatment
Number of subjects: 0
Study 11021270 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 7567587 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% tilt biphasic waveform
Number of subjects: 30
Study 7567587 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% tilt biphasic pulse
Number of subjects: 30
Study 7567587 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% tilt biphasic shocks
Number of subjects: 30
Study 2190054 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied 2% diphemanil methylsulfate
Number of subjects: 15
Study 2190054 — intervention group
Group type: COMPARATOR
Intervention: Topically applied placebo
Number of subjects: 15
Study 340980 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 239
Study 340980 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 239
Study 340980 — intervention group
Group type: EXPERIMENTAL
Intervention: Total series
Number of subjects: 239
Study 30844507 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative lidocaine infusion (1.5mg/kg bolus followed by 2 mg/kg/h)
Number of subjects: 100
Study 30844507 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative pregabalin (300mg preoperatively, 75mg twice daily for 9 days)
Number of subjects: 100
Study 30844507 — intervention group
Group type: COMPARATOR
Intervention: Placebo for lidocaine
Number of subjects: 100
Study 30844507 — intervention group
Group type: COMPARATOR
Intervention: Placebo for pregabalin
Number of subjects: 100
Study 28043872 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed casein formula (EHCF) + Lactobacillus rhamnosus GG (LGG)
Number of subjects: 220
Study 28043872 — intervention group
Group type: COMPARATOR
Intervention: Extensively hydrolyzed casein formula (EHCF)
Number of subjects: 220
Study 25922848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) therapy
Number of subjects: 0
Study 23590727 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 0
Study 23590727 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60/120 mg/day
Number of subjects: 0